A rare case of nodular lymphocyte predominant Hodgkin lymphoma, which developed 5 years after successful treatment of diffuse large B-cell lymphoma

Cover Page

Cite item

Full Text

Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLHLP) – B-cell lymphoma, which has been historically added to the group of Hodgkin's lymphomas, despite the peculiarities of the clinical course, treatment and prognosis, as well as morphological and immunophenotypical differences. In 75% of cases, the disease is detected at early stages (I–II according to Ann Arbor classification), has an indolent course and a favorable prognosis with 10-years an overall survival rate, more than 80%. Despite this, with long-term follow-up and the development of frequent relapses, transformation into diffuse large-cell B-cell lymphoma (DCBCL) or T-lymphocyte/histiocyte-rich DCBCL can occur, isolated cases in children. In the world literature, there are isolated cases of the development of NLHLP after treatment of DCBKL in adults, while among the pediatric population, cases have not been described. This article presents a clinical case of DCBKL in a 10-year-old child who, 5 years after the end of treatment, developed nodular Hodgkin's lymphoma with lymphocytic predominance. The patient's parents agreed to use the information, including the child's photo, in scientific research and publications. 

About the authors

M. A. Senchenko

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

Author for correspondence.
ORCID iD: 0000-0002-9921-5620

Moscow 

Russian Federation

D. S. Abramov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

Email: dmitry.abramov@fccho-moscow.ru
ORCID iD: 0000-0003-3664-2876

MD, pathologist, Pathology Department,

1 Samory Mashela St., Moscow 117997

Russian Federation

A. E. Rudneva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

Moscow 

Russian Federation

E. V. Volchkov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

ORCID iD: 0000-0002-2574-1636

Moscow 

Russian Federation

G. A. Nasirdinova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

ORCID iD: 0000-0002-4978-0496

Moscow 

Russian Federation

D. A. Gobadze

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

Moscow 

Russian Federation

N. V. Myakova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

ORCID iD: 0000-0002-4779-1896

Moscow 

Russian Federation

D. M. Konovalov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation

ORCID iD: 0000-0001-7732-8184

Moscow

Russian Federation

References

  1. Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoidt issues. Lyon: IARC Press; 2017. Рp. 323–5.
  2. Nogová L., Reineke T., Brillant C., Sieniawski M., Rüdiger T., Josting A., et al.; German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26 (3): 434–9. doi: 10.1200/JCO.2007.11.8869
  3. Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531)
  4. Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Brice P., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diff use large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. doi: 10.1002/cncr.24819
  5. Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar A., Dörffel W., Wallace W.H., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.
  6. Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. doi: 10.1097/MPH.0b013e31818a9564
  7. Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. doi: 10.1097/PAS.0b013e318165b0d6
  8. Rudiger T., Gascoyne R.D., Jaff e E.S., de Jong D., Delabie J., Müller-Hermelink H.K., et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13 Suppl 1: 44–51. doi: 10.1093/annonc/13.s1.44
  9. Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt B., Feller A.C., Dörffel W., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21. doi: 10.1055/s-0035-1559664
  10. Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Miao Y., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. doi: 10.1186/s40425-019-0730-x
  11. Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. doi: 10.1098/rstb.2000.0751
  12. Koh K.N., Yoo K.H., Im H.J., Sung K.W., Koo H.H., Kim H.S. et al. Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey. J Korean Med Sci 2016; 31 (8): 1254–61. doi: 10.3346/jkms.2016.31.8.1254
  13. Fianchi L., Pagano L., Piciocchi A., Candoni A., Gaidano G., Breccia M., et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90 (5): E80–5. doi: 10.1002/ajh.23966

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Senchenko M.A., Abramov D.S., Rudneva A.E., Volchkov E.V., Nasirdinova G.A., Gobadze D.A., Myakova N.V., Konovalov D.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.